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Abstract
The increase of the allergic rhinitis incidence is a pressing problem for large industrial cities. The literature 
data of the allergic rhinitis incidence in countries of Europe and Ukraine was analyzed. According to various 
authors allergic rhinitis was registered in 12-24% of the Russian Federation residents, 26-40% - in the USA, 24- 
32% - in France, 16% in the UK, and 19% in Denmark. Three main clinical forms of the allergic rhinitis were 
distinguished: mild, moderate and severe. General pharmacotherapy principles of mild and moderate forms of 
allergic rhinitis are presented in the article. The medicines for first-line therapy of allergic rhinitis group "R01 AD" 
were indicated - drugs acting on the respiratory system, decongestants and other drugs for topical use in diseases 
of the nasal cavity, corticosteroids. The assortment of nasal corticosteroids is presented by mometasone (13 trade 
names), beclamethasone (2 trade names), fluticasone propionate (5 trade names). It is also shown that 95.6% of 
the nasal corticosteroids are imported from 9 countries, mainly from India and Belgium. The Ukrainian spray 
Forinex produced by Pharmac is the only representative among the R01AD group, but according to the pricing 
range it is not a drug of choice among nasal corticosteroids. The data obtained indicate the risks of including only 
imported funds in the insurance list and a low replacement rate with the Ukrainian drug for patients with allergic 
rhinitis.
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Acute rhinosinusitis is one of the leading diseases 
of ENT organs. In the vast majority of cases, it is a com­
plication of acute viral respiratory infection (AVRI). 
About 1 billion cases of viral respiratory tract infections 
are recorded in the world annually, about 6.5% of 
which are complicated by bacterial infection of the pa­
ranasal sinuses. According to various sources, sinusitis 
affects up to 12% of the population in Ukraine and up 
to 42% are patients with sinusitis among patients who 
are in ENT hospitals [7, 8]. The spectrum of infectious- 
inflammatory pathology of the paranasal sinuses of the 
nose and its mucous membranes includes sinusitis, 
frontitis, etmoiditis and sphenoiditis, and in some cases 
they are observed in combination with inflammatory 
diseases of the lungs.
The prevalence of rhinosinusitis is not being de­
creased nowadays. Moreover, there is a tendency to in­
crease the number of recurrent and chronic forms of the 
disease, frequency o f orbital and intracranial complica­
tions development. The main clinical manifestations of 
these diseases -  difficulties in nasal breathing, nasal 
discharge, sneezing, headache -  reduce the quality of 
life of the patients [ 1 ].
The urgency of solving the problem of diagnosis 
and treatment of rhinosinusitis is also due to the fact 
that it goes far beyond otorhinolaryngology and is 
closely related to bronchopulmonary pathology, organ­
ism allergization and changes in local and humoral im­
munity. Rhinosinusitis often causes the development of 
chronic bronchitis, pneumonia, bronchial asthma, aller­
gic rhinitis (AR), etc. [2].
Epidemiological studies in many European coun­
tries have shown that the incidence of allergic rhinitis 
has increased tenfold over the past decade [4]: the re­
sults of these studies indicate that 10-15% of the popu­
lation suffer from AR in the developed countries. In this 
case, AR is more common in urban residents, which is 
associated with increased air pollution in metropolitan 
areas. It has been established that AR can provoke the 
development of other respiratory and ear diseases: in 
24% of cases AR is a risk factor for acute and chronic 
otitis media, and in 28% of cases -  risk of chronic rhi­
nosinusitis [6].
Thus, the urgency of the problem of acute rhinosi­
nusitis accompanied by allergic rhinitis management is 
determined by the high prevalence of this pathology, 
reduced quality of life, economic costs of treatment. In 
the complex pharmacotherapy approach of this syn­
drome complex the important role is played by local 
nasal corticosteroids, which are widely presented in the 
modem pharmaceutical market of Ukraine. The doctor 
and the patient have to choose effective and affordable 
drug that requires marketing and pharmacoeconomic 
evaluation.
The purpose of the study was to conduct a com­
parative marketing analysis o f modem nasal cortico­
steroids and pharmacoeconomic evaluation of treat­
ment of acute rhinosinusitis, accompanied by manifes­
tations of allergic rhinitis according to the “cost 
minimization” methodology, taking into account the 
duration of treatment for 7 days.
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Materials and methods of the study. A compar­
ative analysis of published data on the pharmacody­
namic features of the mechanism of action of nasal cor­
ticosteroids was performed, criteria for the effective­
ness of treatment of acute rhinosinusitis were 
determined. A marketing analysis of the range of nasal 
corticosteroids used for the treatment of acute rhinosi­
nusitis with specified prices as of January 2020 has 
been conducted (http://www.ama.dp.ua/). According to 
the “cost minimization” methodology, the pharmaco- 
economic component of the use of nasal corticosteroids 
was determined [2].
Research results. Nasal corticosteroids are first- 
line drugs in patients with persistent low-grade AR, as 
well as moderate and severe disease. Nasal corticoster­
oids can be administered alone or in combination with 
antihistamines. They can achieve rapid relief of nasal 
breathing and stop the growth of pathogenic microor­
ganisms in the mucous membranes. Proper and regular 
use of nasal corticosteroids reduces the severity of rhi- 
nological symptoms and improves the condition of the 
nasal mucosa. Numerous studies and meta-analyzes 
have shown that nasal corticosteroids significantly out­
perform antihistamines and leukotriene receptor antag­
onists in the control of AR symptoms, including nasal 
obstruction and rhinorrhea. In addition, nasal cortico­
steroid therapy has been reported to improve ophthal­
mic and pulmonary symptoms in patients with concom­
itant asthma and allergic rhinoconjunctivitis. The most 
common side effects when using nasal corticosteroids 
are irritation and burning of the nasal mucosa [7].
One of the important stages of pharmacoeconomic 
evaluation of the use of medicines in various patholog­
ical conditions is the analysis of the range and structure 
of pharmaceutical market. Marketing analysis accord­
ing to the anatomical -  therapeutic and chemical clas­
sification of ATC has revealed 23 nasal corticosteroids 
used in the treatment of AR (http://www.drlz.com.ua). 
which are included in the group R - «Medicines acting 
on respiratory system” and constitute the group RO1A 
-  “Decongestants and other drugs for topical applica­
tion for the diseases of nasal cavity”; R01 AD -  Corti­
costeroids.
In the study of characteristics of the range of nasal 
corticosteroids according to the composition of active 
substances distinguish derivatives of mometasone (13 
trade representatives), beclomethasone (2 trade repre­
sentatives), fluticasone propionate (5 trade representa­
tives) and others. It has also been established that 
95.6% of nasal corticosteroids are imported from the 
country of origin. Unfortunately, Ukraine has only one 
representative -  FORINEX PJSC “Pharmac” with ac­
tive substance mometasone 45eclome monohydrate. 
Imported medicines are represented by 9 producing 
countries, where India and Belgium have the leading 
position -  by 17.4% of the total assortment (Fig. 2).
In the analysis of implementation and consumer 
demand among patients best-selling nasal corticoster­
oids were identified (Table 2). Also, this table presents 
data on the cost of a treatment course for the month ac­
cording to the “cost minimization” methodology.
Table 2
Assortment of nasal corticosteroids
Trade name Dose Price The cost o f treatment 
course, UAH
Beclomethasone
Beconase | 50 mkg/dose, 180 доз | 183,77 I 61,2
Fluticasone
Avamis
27,5 mkg/dose, 120 doses 238,31 119,15
27,5 mkg/dose, 30 doses 182,3 182,3
Nasofan 50 mkg/dose, 120 doses 455,9 227,9
Mometasone
Allertec Naso 50 mkg/dose, 60 doses 175,3 175,3
50 mkg/dose, 140 doses 211,12 90,48
Glenspray
50 mkg/dose, 120 doses 213,2 106,6
50 mkg/dose, 60 doses 163,48 163,48
50 mkg/dose, 150 doses 308,66 123,4
Nasonex Sinus 50 mkg/dose, 60 doses 281,75 281,75
50 mkg/dose, 140 doses 406,38 174,16
Flix
50 mkg/dose, 140 doses 270,62 115,98
50 mkg/dose, 70 doses 209,76 179,79
Forinex 50 mkg/dose, 140 doses 250,0 107,14
Thus, we have shown that there is a wide range of 
both -  manufacturers and price levels among the nasal 
corticosteroids. More accessible today according to this 
site http://www.ama.dp.ua/ is Allertec Naso 211,12 
UAFI, with a course of treatment for a month -  90,48 
UAFI. Ukrainian Forinex spray holds an intermediate 
position in terms of price for packaging -  250,0 and for 
the cost of treatment -  107,14 UAFI.
Conclusion. Summarizing the information pre­
sented, it is established that Ukrainian market for drugs 
of the first line of allergic rhinitis treatment is repre­
sented by imported nasal corticosteroids (the leaders of 
representatives are the countries of India and Belgium 
for 17.4% of the total group assortment). Nasal cortico­
steroids are widely represented by active ingredients, 
namely, 45eclomethasone, fluticasone, mometasone
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and combination agents, with a total of 23 trading posi­
tions in the market. The FORINEX, domestic spray 
produced by PFIARMAC is the only representative of 
the R01AD group, but it is not a drug of choice among 
the nasal corticosteroids in terms of pricing and cost.
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Аннотация
Проблемы, связанные с этиологией, патогенезом, клинической картиной, диагностикой, лечением и 
профилактикой острых эрозий и язв органов пищеварения у хирургических больных, обсуждаются на ос­
нове результатов комплексного обследования более 70 пациентов и информации в литературе. Предложен 
рациональный алгоритм лечения перфоративных язв, а также кровоточащих язв и эрозий, определены по­
казания к операции и предложен новый основной этап при различных методах хирургического вмешатель­
ства при оперативном лечении перфоративных язв, а также кровоточащих язв и эрозий.
Abstract
The problems associated with the etiology, pathogenesis, clinical presentation, diagnosis, treatment and pre­
vention of acute erosion and ulceration of the digestive organs in surgical patients are discussed based on the 
results of a comprehensive examination of more than 71 patients and information in the literature. A rational 
algorithm is proposed for the treatment of perforated ulcers, as well as bleeding ulcers and erosions, indications
